ImmuCell Corporation — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; the supplied text does not provide a separate fourth-quarter income statement.
Business context
ImmuCell develops and sells animal-health products for dairy and beef cattle. Its established First Defense product line prevents scours in newborn calves; Re-Tain, a treatment for subclinical mastitis in dairy cows, remained in development and had no product sales. First Defense generated 99% of 2022 product sales.
Financial results and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Product sales | $18.57 million | $19.24 million |
| Gross margin | $7.65 million; 41% of sales | $8.66 million; 45% of sales |
| Operating income (loss) | $(2.30) million | $0.26 million |
| Net income (loss) | $(2.49) million; $(0.32) per share | $(0.08) million; $(0.01) per share |
| Cash from operations | $(1.54) million | $0.95 million |
| Capital expenditures | $3.98 million | $2.61 million |
- Sales fell 4%. U.S. sales rose 2%, while international sales declined 41%; international sales represented 8% of total sales, versus 14% in 2021.
- Gross margin declined by $1.01 million. A $588,000 inventory write-off, principally related to contamination, reduced the 2022 margin; management estimated margin would have been approximately 44% without that charge.
- Cash and cash equivalents were $5.79 million at year-end, down from $10.19 million. Net working capital was $10.92 million, down from $13.73 million. Inventory increased to $6.04 million from $3.09 million.
- Total debt obligations, including current and long-term portions, were approximately $10.23 million, compared with approximately $9.14 million in 2021. The company reported approximately $1.4 million of scheduled principal and interest payments in each of 2023 and 2024.
- Management said cash, together with anticipated gross margin from product sales, should fund planned working capital, capital expenditures, and operations for at least 12 months from the filing date.
Material changes and operating developments
- Operating results shifted from a small operating profit in 2021 to a $2.30 million operating loss in 2022, reflecting lower gross margin and higher operating expenses. Product development expense was $4.49 million, sales and marketing expense $3.19 million, and administrative expense $2.26 million.
- First Defense capacity expansion to approximately $30 million of annual sales capacity was completed by the end of 2022. Actual capacity depends on yields, product mix, selling prices, and other factors.
- Production contamination late in 2022 caused the $588,000 inventory charge. A further contamination event was detected in the first quarter of 2023; the company slowed production for investigation, sanitization, and remediation.
- The order backlog was approximately $2.5 million at December 31, 2022 and approximately $8 million on March 10, 2023. Management cautioned that the later figure includes old, duplicate, and potentially cancellable orders.
Outlook, risks, and unusual items
- Management expected first-quarter 2023 production of approximately $3.2 million to $3.4 million, about 56% below its $7.5 million quarterly production target, and anticipated reduced first-quarter sales. The 2023 contamination-related charge was estimated at up to approximately $200,000, including about $114,000 of product still under evaluation.
- Because of lost gross margin from the production slowdown, management deferred portions of planned spending, including further First Defense capacity expansion toward $40 million annually and investment in Re-Tain manufacturing capabilities.
- Re-Tain required FDA approval before sales. Four of five major technical sections were complete; the Chemistry, Manufacturing and Controls section remained outstanding, with a pre-approval facility re-inspection a key requirement. Management was preparing a third submission and said sales could begin around the end of 2023 if approval followed the anticipated timeline.
- Conditional Re-Tain sales estimates were approximately $1 million in 2024 and $2 million in 2025, assuming approval and launch around the end of 2023. Management’s longer-term goals were to exceed 2022 product sales as soon as possible and reach more than $35 million in annual total product sales within five years after Re-Tain’s launch. These are goals, not guaranteed outcomes.
- The bank waived the 2022 debt-service coverage covenant after the company’s reported ratio was 0.44. The 2023 covenant was also waived; a 1.35 minimum ratio applies to specified 2024 measurement periods and thereafter. Failure to meet future requirements could affect financing terms.
- Key risks include further contamination or yield problems, customer losses from supply constraints, inflation and supply-chain costs, dependence on First Defense and two distributors, Re-Tain regulatory and commercialization delays, debt service, and the need to change farm treatment practices for Re-Tain.
- Management identified two 2022 operating-control weaknesses involving deferred compensation accruals and lease accounting, and stated they were remediated by year-end. The independent auditor issued an unqualified opinion on the financial statements; inventory valuation was identified as a critical audit matter.
Important facts for investors to verify
- Whether contamination remediation restored reliable production, improved yields, and reduced the backlog without material additional scrap or customer attrition.
- Actual 2023 sales, production, cash use, and capital spending versus management’s disclosed estimates and deferred projects.
- The status and outcome of the third FDA CMC submission and facility re-inspection, and whether Re-Tain approval and launch timing remain achievable.
- Compliance with the revised debt-service coverage tests, scheduled debt payments, and continued liquidity under operating losses and investment needs.
- Whether gross margin recovers from 41%, and whether customer and distributor concentration remains a significant credit and sales risk.